Aprea Therapeutics Inc (APRE) — Cash Flow-to-Debt Ratio
Aprea Therapeutics Inc (APRE) has a Cash Flow-to-Debt Ratio of -0.88x as of December 2025, meaning its operating cash flow of $-3.07 Million could theoretically repay -1% of its total liabilities ($3.49 Million) in one year. See APRE working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aprea Therapeutics Inc Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for Aprea Therapeutics Inc across 10 annual periods. Also explore Aprea Therapeutics Inc (APRE) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aprea Therapeutics Inc (2007–2025)
Year-by-year debt coverage analysis for Aprea Therapeutics Inc. For market capitalisation and broader financial context, see market value of Aprea Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.69x | $-12.89 Million | $3.49 Million | ▼ -27.3% |
| 2024 | -2.90x | $-13.56 Million | $4.67 Million | ▼ -4.5% |
| 2023 | -2.78x | $-12.18 Million | $4.39 Million | ▲ +49.9% |
| 2022 | -5.54x | $-25.01 Million | $4.51 Million | ▼ -7.6% |
| 2021 | -5.15x | $-37.69 Million | $7.32 Million | ▼ -89.9% |
| 2020 | -2.71x | $-41.80 Million | $15.41 Million | ▲ +4.9% |
| 2019 | -2.85x | $-26.71 Million | $9.36 Million | ▼ -2096.8% |
| 2018 | -0.13x | $-15.25 Million | $117.46 Million | ▲ +43.9% |
| 2017 | -0.23x | $-14.00 Million | $60.53 Million | ▲ +70.4% |
| 2007 | -0.78x | $-1.90 Million | $2.43 Million | — |